The University of Kansas Heartland Institute for Clinical and Translational Research (HICTR) was established in 2007 in response to the national CTSA initiative. The vision of the HICTR is to improve the health of Kansans by creating a novel and transformative translational research enterprise from bench to bedside to community. Particular strengths of our HICTR program are an entrepreneurial drug and device discovery and development program and a well-developed and highly accomplished community-based research program.
The specific aims of the HICTR are to: 1) create a new academic home with innovative training programs for clinical and translational Investigators;2) provide an enhanced coordinated translational research infrastructure;and 3) actively engage the community in developing, testing, and disseminating research, by capitalizing on and expanding existing networks, to improve the health of all Kansans?especially those in rural, underserved and other target communities. The proposed infrastructure and educational programs of the HICTR will address the challenges facing clinical and translational investigators by enhancing and integrating existing resources for easier access, developing new innovative resources, and capitalizing on resources residing in research centers across the university?including our KINBRE and five COBRE grants~and our HICTR network institutions. In support of our aims, we have marshaled an impressive array of institutional, corporate, and community resources in planning, developing, and establishing the HICTR. The HICTR will provide new infrastructure and training and educational programs to support investigators'clinical and translational research?taking laboratory discoveries to first trials in humans (Tl research) and moving research through to studies on dissemination and implementation of research findings to practice (T2 research). With extraordinary institutional and community support, we already have made tremendous progress. Funding from the CTSA program will allow the University of Kansas'HICTR the opportunity to fully realize its potential not only for our region, but also to contribute to the national CTSA Consortium.

Public Health Relevance

The University of Kansas Heartland Institute for Clinical and Translational Research is an academic home for clinical and translational research, providing support to scientists and involving the community, so that discoveries and research findings wi|l be brought more rapidly to the point of care, thus improving the health of all Kansans.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
5UL1TR000001-04
Application #
8638994
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Program Officer
Merchant, Carol
Project Start
2011-06-01
Project End
2016-02-29
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
4
Fiscal Year
2014
Total Cost
$3,225,880
Indirect Cost
$817,090
Name
University of Kansas
Department
Neurology
Type
Schools of Medicine
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Searl, Jeff; Knollhoff, Stephanie; Barohn, Richard J (2017) Lingual-Alveolar Contact Pressure During Speech in Amyotrophic Lateral Sclerosis: Preliminary Findings. J Speech Lang Hear Res 60:810-825
Woolbright, Benjamin L; Ding, Wen-Xing; Jaeschke, Hartmut (2017) Caspase inhibitors for the treatment of liver disease: friend or foe? Expert Rev Gastroenterol Hepatol 11:397-399
Clausen, Ashley N; Billinger, Sandra A; Sisante, Jason-Flor V et al. (2017) Preliminary Evidence for the Impact of Combat Experiences on Gray Matter Volume of the Posterior Insula. Front Psychol 8:2151
Britt, Nicholas S; Patel, Nimish; Shireman, Theresa I et al. (2017) Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia. J Antimicrob Chemother 72:535-542
Nollen, Nicole L; Mayo, Matthew S; Clark, Lauren et al. (2017) Tobacco toxicant exposure in cigarette smokers who use or do not use other tobacco products. Drug Alcohol Depend 179:330-336
Kandel, Sylvie E; Han, Lyrialle W; Mao, Qingcheng et al. (2017) Digging Deeper into CYP3A Testosterone Metabolism: Kinetic, Regioselectivity, and Stereoselectivity Differences between CYP3A4/5 and CYP3A7. Drug Metab Dispos 45:1266-1275
Brosnahan, Godela; Abebe, Kaleab Z; Rahbari-Oskoui, Frederic F et al. (2017) Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials. Curr Hypertens Rev :
Torres, Vicente E; Abebe, Kaleab Z; Schrier, Robert W et al. (2017) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 91:493-500
Yu, Alan S L; Shen, Chengli; Landsittel, Douglas P et al. (2017) Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int :
D?Silva, Linda J; Staecker, Hinrich; Lin, James et al. (2017) Otolith Dysfunction in Persons With Both Diabetes and Benign Paroxysmal Positional Vertigo. Otol Neurotol 38:379-385

Showing the most recent 10 out of 245 publications